I agree and think that the claims that there will be no significant news until 2016 are misguided at best and (in the case of some of the claims made at other sites) deliberately misleading in some cases.

We have any number of data points that could come very soon. Not just Kevetrin, but Brilacidin-OM easily could have some kind of preliminary data well before the end of the year. There are other possible news items -- new clinical trials, preliminary data on Prurisol, and who knows what else that could come out at any time. This stock is so ludicrously undervalued that it should not take much to get it a lot higher than it is here.